Bariatric Biobank of Manitoba, Canada

Registration Status: Completed

Objective: The Manitoba Bariatric Surgery Biobank will store blood, adipose tissue and skeletal muscle samples collected from patients during bariatric surgery. Biomarker profiles will be determined and compared to those of samples collected 1- and 2-years following surgery. One of our objectives is to evaluate the relationship of clinical and metabolic factors as well as adipokine and cytokine profiles on pre- and post- excess body weight loss (1-year and 2-year) and remission/relapse of bariatric surgery outcomes (Type 2 diabetes mellitus, hypertension, dyslipidemia, depression). Being able to determine a pattern in biomarker profiles that may predict diabetes recidivism or failure of excess weight loss following bariatric surgery will provide the opportunity to tailor healthcare delivery to individual needs. The breadth of the negative impacts of obesity, including increased morbidity and mortality, reduction in quality of life, and substantial health care expenditures provides the impetus to discover innovative, integrated, and effective clinical treatment strategies and to build infrastructure that supports collaborative multidisciplinary research. The Manitoba Bariatric Biobank will be a pivotal contribution to surgical research and is an innovative approach to facilitating collaborative research with significant disruptive potential.

Registered Biobank Name	Bariatric Biobank of Manitoba
Biobank Leader	Dr. Krista Hardy
Country	Canada
Email for biobank inquiries	khardy@sbgh.mb.ca
Principal Investigator	Dr. Krista Hardy
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).